Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -18.49%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The call presented a strong positive outlook with significant growth in key areas such as revenue and strategic collaborations, alongside challenges including higher than expected rebates and revised revenue guidance. However, the highlights, particularly the strong growth and strategic partnerships, outweigh the lowlights, indicating positive sentiment.Company Guidance
During the Amicus Therapeutics First Quarter 2025 Financial Results Conference Call, the company provided guidance that highlights several key metrics. The company reported a total revenue growth of 13% year-over-year, reaching $125.2 million, with a constant exchange rate growth of 15%. The revenue from Galafold reached $104.2 million, showing a 6% increase at constant exchange rates, while Pombiliti and Opfolda revenues increased by 92% to $21 million. Despite a higher-than-expected VPAG rebate in the UK impacting revenues, Amicus remains confident in achieving its full-year 2025 growth guidance for Galafold and revised its revenue growth guidance for Pombiliti and Opfolda to 50% to 65%. The company projects to reach combined sales of $1 billion by the end of 2028 for its two key products. Amicus also anticipates achieving GAAP profitability in the second half of 2025. The strategic collaboration with Dimerix and the expansion of their global supply chain further contribute to the company's positive outlook.Strong Double-Digit Revenue Growth
Amicus delivered its eleventh consecutive quarter of double-digit sales growth in its core business in Pompe and Fabry, with expectations for this trend to continue for years.
Strategic Collaboration with Dimerix
Amicus entered into a strategic collaboration with Dimerix, acquiring U.S. commercialization rights to DMX-200, a first-in-class compound in late Phase III development for a rare fatal kidney disease, with blockbuster market potential.
Onshoring Manufacturing to Strengthen Supply Chain
Amicus announced onshoring a portion of its drug product manufacturing to enhance its diversification strategy.
Galafold Revenue Growth and Market Share
Galafold revenue reached $104.2 million, up 6% at constant exchange rates, with a 14% increase in new patient starts and a 69% global market share of treated Fabry patients with amenable mutations.
Pombiliti and Opfolda Revenue Growth
Pombiliti and Opfolda revenue reached $21 million, up 92% at constant exchange rates, driven by significant growth in the U.S., Germany, and Spain.
Positive Outlook for DMX-200
The Phase III ACTION study for DMX-200 is progressing well, with FDA alignment on proteinuria as the primary endpoint for approval.
FOLD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FOLD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $7.68 | $6.68 | -13.02% |
Feb 19, 2025 | $9.85 | $9.56 | -2.94% |
Nov 06, 2024 | $11.74 | $11.24 | -4.26% |
Aug 08, 2024 | $10.00 | $11.32 | +13.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amicus Therapeutics (FOLD) report earnings?
Amicus Therapeutics (FOLD) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Amicus Therapeutics (FOLD) earnings time?
Amicus Therapeutics (FOLD) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FOLD EPS forecast?
FOLD EPS forecast for the fiscal quarter 2025 (Q2) is -0.11.